The UK has become the world’s fourth largest exporter, but can it maintain this momentum? 
Why the government’s haste in changing the health system could come back to haunt it 
PUMA Unveils 'Be You' Edition of the MB.03 Before Launching LaMelo Ball's Newest MB.04 Sneaker 
Good for your health and the environment: why we should be eating oily fish 
Cycling: The untapped potential for improving our health (and the climate) 
Novavax, Sanofi Ink Deal to Commercialize COVID-19 Vaccine to Jointly Produce Combination Shots 
Half our colleagues suffer pain and discomfort from periods. But they’re still a taboo subject at work 
Some experts say the US economy is on the up, but here’s why voters don’t think so 
PepsiCo India Takes Steps to Make Lay’s Chips Healthier to Phase out of Palm Oil 
SEC Opens Investigation into Boeing Co. over Safety Statements 
Elon Musk Teases Revolutionary Full Self-Driving V12.4, Cybertruck to Wait 
Reducing energy demand and improving efficiency will help prevent the next gas crisis 
Flavoured vapes may produce many harmful chemicals when e-liquids are heated – new research 
What if the Reserve Bank itself has been feeding inflation? An economist explains 
How does the drug abemaciclib treat breast cancer? 
Pfizer Inc.’s planned delivery of critical new medicines, such as respiratory syncytial virus (RSV) vaccine, to low-income nations, is likely to be delayed by several years due to several issues.
According to global health officials, Pfizer has not yet taken some of the necessary actions to make the vaccine accessible in developing nations.
They include getting the shot approved by the WHO and by nonprofit organizations that finance purchases in low-income countries, such as the global vaccine alliance Gavi.
Furthermore, the health agency prefers syringes that are automatically disabled after one injection for safety reasons to prevent reuse, but Pfizer's RSV vaccine is not made for those syringes.
Additionally, the RSV shot is only presently offered in single-dose vials. Multi-dose vials are frequently utilized in situations with less resources since they are less expensive and easier to distribute.
Preservatives must be added to multi-dose vials, therefore the manufacturer must do further tests to make sure there will be no impact on the vaccine's safety or effectiveness.
The vaccine will need a different delivery system to be used in developing countries in Africa and Asia, including alternative packaging and syringes.
Preparations for those modifications are just beginning, according to the World Health Organization.
Pfizer committed to more equitable access last year, following criticism that it prioritized wealthy nations for doses of its COVID-19 shot early in the pandemic. The company says it wants to shorten a timeline in which poorer countries often get vaccines many years after they are available elsewhere.
The drugmaker received a $28 million grant from the Bill and Melinda Gates Foundation in September to support the launch of the RSV vaccine in poorer countries, where RSV, a common cold-like virus, is much more likely to be lethal for very young children.
Pfizer's maternal RSV vaccine is expected to be approved for use in pregnant women in August in the US and several months later in Europe. Its peak sales forecast is more than $2 billion annually, together with the maternal vaccine and an RSV shot for older adults.
